BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15252852)

  • 1. Association between female breast cancer and cutaneous melanoma.
    Goggins W; Gao W; Tsao H
    Int J Cancer; 2004 Sep; 111(5):792-4. PubMed ID: 15252852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevation of thyroid cancer risk among cutaneous melanoma survivors.
    Goggins W; Daniels GH; Tsao H
    Int J Cancer; 2006 Jan; 118(1):185-8. PubMed ID: 16049985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study.
    Spanogle JP; Clarke CA; Aroner S; Swetter SM
    J Am Acad Dermatol; 2010 May; 62(5):757-67. PubMed ID: 20223559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer.
    Yang GB; Barnholtz-Sloan JS; Chen Y; Bordeaux JS
    Arch Dermatol; 2011 Dec; 147(12):1395-402. PubMed ID: 22184761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of second primary breast cancer among cancer survivors: Implications for prevention and screening practice.
    Cheng Y; Huang Z; Liao Q; Yu X; Jiang H; He Y; Yao S; Nie S; Liu L
    PLoS One; 2020; 15(6):e0232800. PubMed ID: 32497148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin.
    Balamurugan A; Rees JR; Kosary C; Rim SH; Li J; Stewart SL
    J Am Acad Dermatol; 2011 Nov; 65(5 Suppl 1):S69-77. PubMed ID: 22018070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma.
    Goggins WB; Finkelstein DM; Tsao H
    Cancer; 2001 Feb; 91(4):874-80. PubMed ID: 11241258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival.
    Herr MM; Schonfeld SJ; Dores GM; Withrow DR; Tucker MA; Curtis RE; Morton LM
    J Natl Cancer Inst; 2018 Nov; 110(11):1248-1258. PubMed ID: 29659938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial and ethnic differences in risk of second primary cancers among breast cancer survivors.
    Calip GS; Law EH; Ko NY
    Breast Cancer Res Treat; 2015 Jun; 151(3):687-96. PubMed ID: 26012645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer.
    Nagore E; Montoro A; García-Casado Z; Botella-Estrada R; Insa A; Lluch A; López-Guerrero JA; Guillén C
    Melanoma Res; 2009 Aug; 19(4):211-4. PubMed ID: 19571771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors.
    Goggins WB; Tsao H
    Cancer; 2003 Feb; 97(3):639-43. PubMed ID: 12548605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
    Kaplan HG; Malmgren JA; Li CI; Calip GS
    Breast Cancer Res Treat; 2013 Dec; 142(3):629-36. PubMed ID: 24265034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
    Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
    Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
    Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
    Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer in thyroid cancer survivors: An analysis of the Surveillance, Epidemiology, and End Results-9 database.
    Kuo JH; Chabot JA; Lee JA
    Surgery; 2016 Jan; 159(1):23-9. PubMed ID: 26522696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006.
    Jemal A; Saraiya M; Patel P; Cherala SS; Barnholtz-Sloan J; Kim J; Wiggins CL; Wingo PA
    J Am Acad Dermatol; 2011 Nov; 65(5 Suppl 1):S17-25.e1-3. PubMed ID: 22018063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
    J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonendocrine cancers associated with benign and malignant parathyroid tumors.
    Fallah M; Kharazmi E; Sundquist J; Hemminki K
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1108-14. PubMed ID: 21525164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the current state of melanoma incidence.
    Little EG; Eide MJ
    Dermatol Clin; 2012 Jul; 30(3):355-61. PubMed ID: 22800543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.